Business

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

Financial Post · September 17, 2026 at 4:19 p.m.

CAMBRIDGE, Mass., Sept.

17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology (CJASN).

The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Society of Paediatric Nephrology (ESPN).

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

More from Financial Post

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

More in Business

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

William Watson: In new pamphlet, U.K.’s Kemi Badenoch points the (right) way

Pipeline, major projects shows Ottawa’s commitment to Alberta, Smith says